Research and Clinical Trials

Title  
A Phase III randomized, placebo controlled, double-blind trial of sorafenib plus erlotinib vs. sorafenib plus placebo as first line systemic treatment for hepatocellular carcinoma (HCC – liver cancer)
Brief Description  
This is a randomized study to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A hepatocellular carcinoma (HCC - liver cancer). Patients who are candidates for potentially curative intervention (i.e. surgical resection or transplant ) are not eligible for this study.
Who may be Eligible  
Male or Female patients at least 18 years of age with unresectable Hepatocellular Carcinoma
Speciality/Disorder  
Liver cancer
IRB Number  
CHS1-10-029
Principal Investigator  
Russo, Mark

For More Information, Contact  Gale  W, Groseclose
Phone:  (704) 355-4875  Fax:  (704) 355-8147  
Email:  gale.groseclose@carolinashealthcare.org
Address:Carolinas Medical Center 1000 Blythe Boulevard Charlotte, NC 28232
Close